Clavamox is stable in the presence of gastric acid and is not significantly influenced by gastric or intestinal contents. The 2 components are rapidly absorbed resulting in amoxicillin and clavulanic acid concentrations in
clavamox 125 mg, urine, and tissues similar to those produced when each is administered alone. Amoxicillin and clavulanic acid diffuse readily into most body tissues and fluids with the exception of brain and spinal fluid, which amoxicillin penetrates adequately when meninges are inflamed. Most of the amoxicillin is
clavamox liquid excreted unchanged in the urine. Clavulanic acid’s penetration into spinal fluid is unknown at this time. Approximately 15% of the administered dose of clavulanic acid is excreted in the urine within the first 6 hours.
Clavamox combines the
tetracycline and amoxicillin distinctive properties of a broad-spectrum antibiotic and a ?-lactamase inhibitor to effectively extend the antibacterial spectrum of amoxicillin to include ?-lactamaseproducing as well as non-?-lactamase-producing aerobic and anaerobic organisms. The susceptibility of these organisms has also been demonstrated in
clavamox 375 mg, vivo studies. Studies have demonstrated that both aerobic and anaerobic flora are isolated from gingival cultures of dogs with clinical evidence of peridontal disease. Both gram-positive and gram-negative aerobic and
clavamox canine reactions, isolates indicate sensitivity to amoxicillin/ clavulanic acid during antimicrobial susceptibility testing.